J&J Said to Sell Tasmanian Opium-Poppy Processor to SK Capital

  • Tasmanian Alkaloids sale expected to be completed by mid-year
  • U.S. private equity firm already has contract-drug business

Johnson & Johnson has agreed to sell an opium-poppy processing business in the Australian state of Tasmania to U.S. private equity firm SK Capital Partners LP, according to a person familiar with the transaction.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.